In a study with CD22 CAR-T cells for r/r B-ALL (ChiCTR-OIC-17013523), 24 of 30 patients achieved CR within 1 month, and the 12-month leukemia-free survival rate for patients was 71.6%, with most patients experiencing only minor adverse effects. Here, CD22 is linked to acute lymphoblastic leukemia.